The Glomerular Podocyte as a Target of Growth Hormone Action: Implications for the Pathogenesis of Diabetic Nephropathy

Current Diabetes Reviews

Volumn 7, Issue 1, 2011, Pages 50-55

  Kumar, P Anil ^a   Brosius III, Frank C ^b   Menon, Ram K ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Diabetic nephropathy; Growth hormone; Podocyte; Review

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; OCTREOTIDE; PTR 3173; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

DIABETIC NEPHROPATHY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; GROWTH HORMONE DEFICIENCY; HORMONE ACTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; KIDNEY STRUCTURE; MICROALBUMINURIA; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; REVIEW; TARGET CELL; TRANSGENIC ANIMAL;

EID: 79952757250     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339911794273900     Document Type: Review

References (84)

1. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009; 30: 152-177.
2. Baumann G. Growth hormone binding protein. J Pediatr Endocri-nol Metab 2001; 14: 355-375.
3. Smith JR, Benghuzzi H, Tucci M, et al. The effects of growth hormone and insulin-like growth factor on the proliferation rate and morphology of RAW 264.7 macrophages. Biomed Sci Instrum 2000; 36: 111-116.
4. Pantaleon M, Whiteside EJ, Harvey MB, et al. Functional growth hormone (GH) receptors and GH are expressed by preimplantation mouse embryos: a role for GH in early embryogenesis? Proc Natl Acad Sci USA 1997; 94: 5125-5130.
5. Han X, Ren X, Jurickova I, et al. Regulation of intestinal barrier function by signal transducer and activator of transcription 5b. Gut 2009; 58: 49-58.
6. Lu C, Schwartzbauer G, Sperling MA, et al. Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J Biol Chem 2001; 276: 22892-22900.
7. Baudet ML, Rattray D, Martin BT, Harvey S. Growth hormone promotes axon growth in the developing nervous system. Endocrinology 2009; 150: 2758-2766.
8. Reddy GR, Pushpanathan MJ, Ransom RF, et al. Identification of the glomerular podocyte as a target for growth hormone action. Endocrinology 2007; 148: 2045-2055.
9. Ferry RJ, Jr., Cerri RW, Cohen P. Insulin-like growth factor bind-ing proteins: new proteins, new functions. Horm Res 1999; 51: 53-67.
10. U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of ESRD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2009.
11. Ruggenenti P, Remuzzi G. Nephropathy of type-2 diabetes melli- tus. J Am Soc Nephrol 1998; 9: 2157-2169.
12. Feld S, Hirschberg R. Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev 1996; 17: 423-480.
13. Chin E, Zhou J, Bondy CA. Renal growth hormone receptor gene expression: relationship to renal insulin-like growth factor system. Endocrinology 1992; 131: 3061-3066.
14. Chin E, Zhou J, Bondy C. Anatomical relationships in the patterns of insulin-like growth factor (IGF)-I, IGF binding protein-1, and IGF-I receptor gene expression in the rat kidney. Endocrinology 1992; 130: 3237-3245.
15. Johannsson G, Sverrisdottir YB, Ellegard L, et al. GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. J Clin Endocrinol Metab 2002; 87: 1743-1749.
16. Hansen AP. Abnormal serum growth hormone response to exercise in juvenile diabetics. J Clin Invest 1970; 49: 1467-1478.
17. Sperling MA, Wollesen F, DeLamater PV. Daily production and metabolic clearance of growth hormone in juvenile diabetes melli-tus. Diabetologia 1973; 9: 380-383.
18. Hayford JT, Danney MM, Hendrix JA, Thompson RG. Integrated concentration of growth hormone in juvenile-onset diabetes. Diabetes 1980; 29: 391-398.
19. Lorenzi M, Karam JH, McIlroy MB, Forsham PH. Increased growth hormone response to dopamine infusion in insulin-dependent diabetic subjects: indication of possible blood-brain barrier abnormality. J Clin Invest 1980; 65: 146-153.
20. Krassowski J, Felber JP, Rogala H, et al. Exaggerated growth hormone response to growth hormone-releasing hormone in type I diabetes mellitus. Acta Endocrinol (Copenh) 1988; 117: 225-229.
21. Asplin CM, Faria AC, Carlsen EC, et al. Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1989; 69: 239-245.
22. Edge JA, Dunger DB, Matthews DR, et al. Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. J Clin Endocrinol Metab 1990; 71: 1356-1362.
23. Almqvist EG, Groop LC, Manhem PJ. Growth hormone response to the insulin tolerance and clonidine tests in type 1 diabetes. Scand J Clin Lab Invest 1999; 59: 375-382.
24. Bereket A, Lang CH, Wilson TA. Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Horm Metab Res 1999; 31: 172-181.
25. Tamborlane WV, Hintz RL, Bergman M, et al. Insulin-infusion-pump treatment of diabetes: influence of improved metabolic control on plasma somatomedin levels. N Engl J Med 1981; 305: 303-307.
26. Sonksen PH, Russell-Jones D, Jones RH. Growth hormone and diabetes mellitus. A review of sixty-three years of medical research and a glimpse into the future? Horm Res 1993; 40: 68-79.
27. Menon RK, Stephan DA, Rao RH, et al. Tissue-specific regulation of the growth hormone receptor gene in streptozocin-induced diabetes in the rat. J Endocrinol 1994; 142: 453-462.
28. Menon RK, Shaufl A, Yu JH, et al. Identification and characterization of a novel transcript of the murine growth hormone receptor gene exhibiting development- and tissue-specific expression. Mol Cell Endocrinol 2001; 172: 135-146.
29. Menon RK, Arslanian S, May B, et al. Diminished growth hormone-binding protein in children with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1992; 74: 934-938.
30. Mercado M, Molitch ME, Baumann G. Low plasma growth hormone binding protein in IDDM. Diabetes 1992; 41: 605-609.
31. Arslanian SA, Menon RK, Gierl AP, et al. Insulin therapy increases low plasma growth hormone binding protein in children with new-onset type 1 diabetes. Diabet Med 1993; 10: 833-888.
32. Hilding A, Brismar K, Degerblad M, et al. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 1995; 80: 2646-2652.
33. Doi T, Striker LJ, Quaife C, et al. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor-1. Am J Pathol 1988; 131: 398-403.
34. Doi T, Striker LJ, Gibson CC, et al. Glomerular lesions in mice transgenic for growth hormone and insulinlike growth factor-I. I. Relationship between increased glomerular size and mesangial sclerosis. Am J Pathol 1990; 137: 541-552.
35. Yang CW, Striker LJ, Kopchick JJ, et al. Glomerulosclerosis in mice transgenic for native or mutated bovine growth hormone gene. Kidney Int Suppl 1993; 39: S90-S94.
36. Bellush LL, Doublier S, Holland AN, et al. Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice. Endocrinology 2000; 141: 163-168.
37. Flyvbjerg A, Bennett WF, Rasch R, et al. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes 1999; 48: 377-382.
38. Thirone AC, Scarlett JA, Gasparetti AL, et al. Modulation of growth hormone signal transduction in kidneys of streptozotocin-induced diabetic animals: effect of a growth hormone receptor antagonist. Diabetes 2002; 51: 2270-2281.
39. Flyvbjerg A, Frystyk J, Osterby R, Orskov H. Kidney IGF-I and renal hypertrophy in GH-deficient diabetic dwarf rats. Am J Physiol 1992; 262: E956-E962.
40. Gronbaek H, Volmers P, Bjorn SF, et al. Effect of GH/IGF-I deficiency on long-term renal changes and urinary albumin excretion in diabetic dwarf rats. Am J Physiol 1997; 272: E918-E924.
41. Flyvbjerg A, Frystyk J, Thorlacius-Ussing O, Orskov H. Soma-tostatin analogue administration prevents increase in kidney soma-tomedin C and initial renal growth in diabetic and uninephrec-tomized rats. Diabetologia 1989; 32: 261-265.
42. Flyvbjerg A, Marshall SM, Frystyk J, et al. Octreotide administration in diabetic rats: effects on renal hypertrophy and urinary albumin excretion. Kidney Int 1992; 41: 805-812.
43. Gronbaek H, Nielsen B, Frystyk J, et al. Effect of lanreotide on local kidney IGF-I and renal growth in experimental diabetes in the rat. Exp Nephrol 1996; 4: 295-303.
44. Igarashi K, Nakazawa A, Tani N, et al. Effect of a somatostatin analogue (SMS 201-995) on renal function and urinary protein excretion in diabetic rats. J Diabet Complications 1991; 5: 181-183.
45. Landau D, Segev Y, Afargan M, et al. A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse. Kidney Int 2001; 60: 505-512.
46. Segev Y, Landau D, Rasch R, et al. Growth hormone receptor antagonism prevents early renal in nonobese diabetic mice. J Am Soc Nephrol 1999; 10: 2374-2381.
47. Gowri PM, Yu JH, Shaufl A, et al. Recruitment of a repressosome complex at the growth hormone receptor promoter and its potential role in diabetic nephropathy. Mol Cell Biol 2003; 23: 815-825.
48. Christiansen JS, Gammelgaard J, Orskov H, et al. Kidney function and size in normal subjects before and during growth hormone administration for one week. Eur J Clin Invest 1981; 11: 487-490.
49. Cummings EA, Sochett EB, Dekker MG, et al. Contribution of growth hormone and IGF-I to early diabetic nephropathy in type 1 diabetes. Diabetes 1998; 47: 1341-1346.
50. Blankestijn PJ, Derkx FH, Birkenhager JC, et al. Glomerular hy-perfiltration in insulin-dependent diabetes mellitus is correlated with enhanced growth hormone secretion. J Clin Endocrinol Metab 1993; 77: 498-502.
51. Krempf M, Ranganathan S, Remy JP, et al. Effect of long-acting somatostatin analog (SMS 201-995) on high glomerular filtration rate in insulin dependent diabetic patients. Int J Clin Pharmacol Ther Toxicol 1990; 28: 309-311.
52. Serri O, Beauregard H, Brazeau P, et al. Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. JAMA 1991; 265: 888-892.
53. Jacobs ML, Derkx FH, Stijnen T, et al. Effect of long-acting soma-tostatin analog (Somatulin) on renal hyperfiltration in patients with IDDM. Diabetes Care 1997; 20: 632-636.
54. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
55. Brosius FC, 3rd, Alpers CE, Bottinger EP, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2503-2512.
56. Wharram BL, Goyal M, Wiggins JE, et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor trans-gene. J Am Soc Nephrol 2005; 16: 2941-2952.
57. Meyer T, Bennett P, Nelson R. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 1999; 42: 1341-1344.
58. Drenckhahn D, Franke RP. Ultrastructural organization of contractile and cytoskeletal proteins in glomerular podocytes of chicken, rat, and man. Lab Invest 1988; 59: 673-682.
59. Rider L, Tao J, Snyder S, et al. Adapter protein SH2B1beta crosslinks actin filaments and regulates actin cytoskeleton. Mol Endo-crinol 2009; 23: 1065-1076.
60. Reddy GR, Kotlyarevska K, Ransom RF, Menon RK. The podo-cyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy? Curr Opin Nephrol Hypertens 2008; 17: 32-36.
61. Kretzler M, Teixeira VP, Unschuld PG, et al. Integrin-linked kinase as a candidate downstream effector in proteinuria. FASEB J 2001; 15: 1843-1845.
62. Guo L, Sanders PW, Woods A, Wu C. The distribution and regulation of integrin-linked kinase in normal and diabetic kidneys. Am J Pathol 2001; 159: 1735-1742.
63. Li Y, Yang J, Dai C, et al. Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis. J Clin Investig 2003; 112: 503-516.
64. de Paulo Castro Teixeira V, Blattner SM, Li M, et al. Functional consequences of integrin-linked kinase activation in podocyte damage. Kidney Int 2005; 67: 514-523.
65. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1-12.
66. Teixeira Vde P, Blattner SM, Li M, et al. Functional consequences of integrin-linked kinase activation in podocyte damage. Kidney Int 2005; 67: 514-523.
67. von Luttichau I, Djafarzadeh R, Henger A, et al. Identification of a signal transduction pathway that regulates MMP-9 mRNA expression in glomerular injury. Biol Chem 2002; 383: 1271-1275.
68. Kotlyarevska K, Dejkhamron P, Gaddameedi R, et al. GH-dependent regulation of ZEB-2/SIP1 expression in glomerular podocytes: a novel crosstalk between GH and TGF-ß pathways and its implication for the development of diabetic nephropathy. 89th Annual Meeting of the Endocrine Society, San Francisco, CA June 15-18, 2007.
69. Comijn J, Berx G, Vermassen P, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001; 7: 1267-1278.
70. van Grunsven LA, Michiels C, Van de Putte T, et al. Interaction between Smad-interacting protein-1 and the corepressor C-terminal binding protein is dispensable for transcriptional repression of E-cadherin. J Biol Chem 2003; 278: 26135-26145.
71. Kumar P, Kotlyarevska K, Dejkhamron P, et al. Regulation of SIP1 expression in podocytes by growrth hormone. J Biol Chem 2010; 285: 31148-31156.
72. Pasupulati A, Sun J, Inoki K, Menon R. Regulation of Akt/mTOR signaling in podocytes by growth hormone: implications for the pathogenesis of diabetic nephropathy. 91st Annual Meeting of the Endocrine Society, Washington DC June 10-13, 2009.
73. Muller AF, Kopchick JJ, Flyvbjerg A, van der Lely AJ. Growth Hormone receptor antagonists. J Clin Endocrinol Metab 2004; 89: 1503-1511.
74. Amin R, Williams RM, Frystyk J, et al. Increasing urine albumin excretion is associated with growth hormone hypersecretion and reduced clearance of insulin in adolescents and young adults with type 1 diabetes: the Oxford Regional Prospective Study. Clin En-docrinol (Oxf) 2005; 62: 137-144.
75. Landau D, Segev Y, Eshet R, et al. Changes in the growth hor-mone-IGF-I axis in non-obese diabetic mice. Int J Exp Diabetes Res 2000; 1: 9-18.
76. Johansen PB, Segev Y, Landau D, et al. Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue. Exp Diabesity Res 2003; 4: 73-81.
77. Amin R, Schultz C, Ong K, et al. Low IGF-I and elevated testosterone during puberty in subjects with type 1 diabetes developing microalbuminuria in comparison to normoalbuminuric control subjects: the Oxford Regional Prospective Study. Diabetes Care 2003; 26: 1456-1461.
78. Taylor AM, Dunger DB, Grant DB, Preece MA. Somatomedin-C/IGF-I measured by radioimmunoassay and somatomedin bioac-tivity in adolescents with insulin dependent diabetes compared with puberty matched controls. Diabetes Res 1988; 9: 177-181.
79. Munoz MT, Barrios V, Pozo J, Argente J. Insulin-like growth factor I, its binding proteins 1 and 3, and growth hormone-binding protein in children and adolescents with insulin-dependent diabetes mellitus: clinical implications. Pediatr Res 1996; 39: 992-998.
80. Landau D, Domene H, Flyvbjerg A, et al. Differential expression of renal growth hormone receptor and its binding protein in experimental diabetes mellitus. Growth Horm IGF Res 1998; 8: 39-45.
81. Segev Y, Landau D, Marbach M, et al. Renal hypertrophy in hy-perglycemic non-obese diabetic mice is associated with persistent renal accumulation of insulin-like growth factor I. J Am Soc Neph-rol 1997; 8: 436-444.
82. Flyvbjerg A. Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes. Kidney Int Suppl 1997; 60: S12-S19.
83. Landau D, Chin E, Bondy C, et al. Expression of insulin-like growth factor binding proteins in the rat kidney: effects of long-term diabetes. Endocrinology 1995; 136: 1835-1842.
84. Kaufman CR, Catanese VM. Pre-and post-translational regulation of renal insulin-like growth factor binding protein-1 in insulin-deficient diabetes. J Invest Med 1995; 43: 178-186.